What is KPV?

KPV is the three-amino-acid sequence Lys-Pro-Val, corresponding to the C-terminal 11-13 fragment of alpha-melanocyte-stimulating hormone. The appeal is that a very small fragment can preserve anti-inflammatory activity without carrying the full parent hormone identity. [7][1]

Most reader interest centers on gut and barrier inflammation. Murine inflammatory-bowel-disease work, nanoparticle oral-delivery research, and hydrogel delivery studies connect KPV with reduced colitis-model inflammation and local tissue targeting. [5][11][15]

KPV names can collapse several related ideas. KPV, Lys-Pro-Val, and alpha-MSH 11-13 point to the tripeptide fragment, while alpha-MSH, melanocortin agonists, and longer peptide analogs are not interchangeable with the same three-amino-acid sequence. [1][7]

What KPV is investigated for

KPV evidence is grouped by practical use case and oral, topical, and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Inflammatory bowel disease and colitis

Oral

44% Preliminary

KPV is promising for gut inflammation biology, but not a substitute for evidence-based IBD care. [5][11]

Human evidence

Controlled human IBD efficacy trials are not established for KPV. [5][11]

Animal / mechanistic evidence

Murine colitis studies support local anti-inflammatory plausibility through KPV and colon-targeted delivery. [5][11]

General inflammatory signaling

Oral, Topical, Injectable

40% Preliminary

General inflammation control should be treated as an anti-inflammatory mechanism, not proof of broad systemic disease benefit. [7]

Human evidence

Broad anti-inflammatory claims lack controlled human outcomes. [7]

Animal / mechanistic evidence

KPV is a minimal fragment with anti-inflammatory activity in vitro and in vivo models. [7]

Gut barrier repair

Oral

32% Limited

Barrier-repair claims are strongest for local oral or colon-targeted delivery models, not systemic injection. [4][17]

Human evidence

No controlled human trial establishes KPV for intestinal barrier repair or permeability outcomes. [4][17]

Animal / mechanistic evidence

PepT1 uptake, nanoparticle delivery, and KPV-binding hydrogel studies support local gut-barrier and mucosal-repair hypotheses in models. [4][11][17]

Skin, wound, and barrier inflammation

Topical, Injectable

30% Limited

Skin and wound claims remain mechanistically plausible but clinically unvalidated. [7][9]

Human evidence

Human route-specific evidence for skin or wound outcomes is limited. [7][9]

Animal / mechanistic evidence

Alpha-MSH/KPV reviews support anti-inflammatory and protective effects in models. [7][9]

Evidence snapshot

Overall confidence

Preliminary

44%

KPV has a clear alpha-MSH fragment identity and promising inflammatory-disease models. The page should still read as preliminary because mature human efficacy data are absent. [7][5]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

15%

Human evidence

Insufficient

No published Phase 2 or Phase 3 human efficacy program establishes KPV for IBD, skin inflammation, or wound healing. [20][22]

48%

Animal / preclinical

Preliminary

Rodent colitis models and targeted oral-delivery work provide the strongest outcome-oriented support. Human route and disease translation remain unresolved. [5][11][15]

44%

Mechanism support

Preliminary

Alpha-MSH fragment biology supports anti-inflammatory signaling. Route-specific translation is still the key limitation. [7][1]

Forms & administration

KPV appears in oral or sublingual gut-targeted, topical barrier, and injectable systemic protocol contexts. Those routes answer different biological questions. [11][9][20]

Oral

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common oral, sublingual, and injectable protocol ranges fall around 1-2 mg per dose. Topical use is formulation-specific by strength and application area. [11][9]

Frequency

Once- or twice-daily scheduling is the most common app pattern for oral, sublingual, and injectable protocols. [5]

Timing Considerations

Morning or evening works for consistency; gut-focused use is easiest to track when tied to a stable meal or symptom-log routine. [11]

Cycle Length

Common cycles use 4-8 week reassessment windows for symptom trend, trigger exposure, skin photos, stool pattern, and tolerability. [5][11]

What to expect

Weeks 1-2

Gut-focused or skin-focused use may first show quieter stool pattern, less reactive skin, lower itch, or fewer flare spikes when the surrounding routine stays stable. [5][9]

Weeks 4-8

Flare frequency, barrier comfort, and symptom spikes become easier to see as a pattern across a full short cycle. [11][15]

After stopping

Gut or skin calm may hold or drift back toward baseline, especially if diet, wound-care, skin-care, or medication changes continue to shift. [7]

Safety profile

For KPV, oral use raises GI-tolerance and disease-context questions, topical use raises local irritation and formulation questions, and injectable use adds product-quality concerns. Pregnancy, pediatric use, and active IBD or wound-care settings remain higher-caution contexts. [20][22][7]

Common side effects

GI discomfort [11]
Local irritation [9]

Cautions

Active inflammatory disease [5]
Unapproved injectable quality [23]

What we don't know

Route-specific absorption, degradation, tissue exposure, formulation behavior, and dose-response are not settled. [9][11]

Who KPV is not for

Route-specific avoid and medical-review notes:

Active IBD flare without medical care
KPV should not delay evidence-based care for diagnosed inflammatory bowel disease or severe symptoms. [5]
Pregnancy or breastfeeding
Avoid because reproductive and developmental safety are not established. [20]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Immunosuppressive therapy
Immunosuppressive therapy could change infection and inflammatory-disease risk when combined with oral, topical, or injectable KPV; this is a theoretical immune-modulation caution. [7]

Pairing notes

Commonly included in these stacks

GHK-Cu / KPV

GHK-Cu / KPV is a two-peptide skin, barrier, and inflammation-support stack. GHK-Cu supplies the collagen, fibroblast, and matrix-remodeling rationale, while KPV supplies the alpha-MSH-derived anti-inflammatory rationale.

GHK-CuKPV

KLOW Stack

KLOW is a four-component recovery, skin, and inflammation-support stack built around BPC-157, TB-500, GHK-Cu, and KPV. It is used to frame tissue repair, cell migration, skin-matrix remodeling, gut or barrier inflammation, and post-procedure support in one plan.

BPC-157TB-500GHK-CuKPV

Regulatory status

United States

KPV has no FDA-approved oral, topical, or injectable drug use as of 2026-06-21. Its separate 503A question is pending FDA PCAC discussion on July 23, 2026; that process does not establish approval, safety, or effectiveness. [20][22]

Route	FDA drug approval	503A compounding
Oral	Not Approved As of 2026-06-21, KPV was not FDA-approved as an oral, topical, or injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [20][22][23]	Under Review KPV-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [20][22][23]
Topical	Not Approved As of 2026-06-21, KPV was not FDA-approved as an oral, topical, or injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [20][22][23]	Under Review KPV-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [20][22][23]
Injectable	Not Approved As of 2026-06-21, KPV was not FDA-approved as an oral, topical, or injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [20][22][23]	Under Review KPV-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [20][22][23]

Oral

FDA drug approval

Not Approved

As of 2026-06-21, KPV was not FDA-approved as an oral, topical, or injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [20][22][23]

503A compounding

Under Review

KPV-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [20][22][23]

Topical

FDA drug approval

Not Approved

As of 2026-06-21, KPV was not FDA-approved as an oral, topical, or injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [20][22][23]

503A compounding

Under Review

KPV-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [20][22][23]

Injectable

FDA drug approval

Not Approved

As of 2026-06-21, KPV was not FDA-approved as an oral, topical, or injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval. [20][22][23]

503A compounding

Under Review

KPV-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance. [20][22][23]

International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; no approved therapeutic KPV product was found in the reviewed official sources.

Sports & competition

WADA's 2026 Prohibited List does not specifically name KPV, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review. [24]

How it works

KPV is the lysine-proline-valine tripeptide from alpha-MSH, and its main rationale is local anti-inflammatory signaling rather than broad immune suppression. Cell and animal work links KPV with reduced inflammatory signaling in epithelial and immune contexts across barrier tissues. [7][2][5]

Delivery is the practical mechanism problem. Oral gut-targeted work depends on small-peptide transport and formulations that keep KPV active at inflamed intestinal sites; topical work depends on skin penetration and stability. Injectable use should not borrow those local-delivery claims without route-specific exposure data. [4][11][10][12]

Research gaps & open questions

What the current literature has not yet settled about KPV:

Human IBD, skin, and wound trials are needed to move KPV beyond preclinical anti-inflammatory plausibility. [5][11]

Oral, topical, and injectable pharmacokinetics should be studied separately because route and formulation are central to interpretation. [9][15]

Combination use with repair peptides needs stack-level safety and efficacy review before public recommendation. [7]

Common questions

What is KPV?

KPV is Lys-Pro-Val, a three-amino-acid alpha-MSH fragment studied for local anti-inflammatory signaling in gut, skin, and barrier models. [7]

Is KPV proven for IBD?

No. Oral and gut-targeted KPV rationale comes from animal and formulation studies, not approved human IBD treatment evidence. [5][11]

Is KPV FDA-approved?

No. KPV has no FDA-approved oral, topical, or injectable drug use, and the July 23, 2026 PCAC discussion is not approval. [20][22]

Myths & misconceptions

Myth

Anti-inflammatory means safe for any flare.

Reality

Anti-inflammatory mechanism does not make KPV a substitute for medical care in IBD, infection, or complex skin disease. [5]

Myth

Oral, topical, and injectable KPV are interchangeable.

Reality

Route and formulation matter because gut targeting, skin delivery, and systemic exposure answer different questions. [9][11]

History & discovery

KPV came from alpha-MSH fragment work, where researchers narrowed anti-inflammatory activity to the C-terminal Lys-Pro-Val sequence instead of treating the full melanocortin hormone as the only active unit. [7][1]

Biochemistry and peptide-conformation studies helped define KPV as a compact tripeptide motif tied to alpha-MSH anti-inflammatory signaling. [7][1]

Murine inflammatory bowel disease models connected KPV with intestinal inflammation, PepT1 transport, and barrier-repair hypotheses. [5]

Nanoparticle and hydrogel studies shifted the field toward oral or local delivery systems, while leaving controlled human efficacy unresolved in practice. [11][15]

Published research 24 studies

[1]

Conformational analysis of tripeptide Ac-Lys-Pro-Val-NH2, COOH-terminal sequence of alpha-MSH.

The Journal of pharmacy and pharmacology, 2001 Jul. review.

[2]

Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.

The Journal of pharmacology and experimental therapeutics, 2003 Aug. review.

[3]

alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.

The Journal of investigative dermatology, 2004 Apr. in vitro.

[4]

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

Gastroenterology, 2008 Jan. review.

[5]

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.

Inflammatory bowel diseases, 2008 Mar. animal.

[6]

Structure-antifungal activity relationship of His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 and analogues.

Bioorganic & medicinal chemistry, 2008 Apr 15. review.

[7]

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

Endocrine reviews, 2008 Aug. review.

[8]

Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.

International journal of physiology, pathophysiology and pharmacology, 2012. in vitro.

[9]

Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.

Biomedical chromatography : BMC, 2015 May. review.

[10]

Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.

Cellular and molecular gastroenterology and hepatology, 2016 May. animal.

[11]

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Molecular therapy : the journal of the American Society of Gene Therapy, 2017 Jul 5. review.

[12]

Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.

Journal of pharmaceutical sciences, 2017 Jul. review.

[13]

Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue.

PloS one, 2018. review.

[14]

Potent and prolonged melanotropic activities of the alpha-MSH fragment analog, Ac-[Nle4,D-Phe7]-alpha-MSH4-9-NH2.

Biochemical and biophysical research communications, 1986 Jun 13. review.

[15]

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.

ACS biomaterials science & engineering, 2021 Oct 11. animal.

[16]

In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis.

Biomaterials science, 2021 Dec 21. review.

[17]

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.

Acta biomaterialia, 2022 Apr 15. review.

[18]

KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.

Advanced healthcare materials, 2024 Dec. review.

[19]

Cyclic melanotropins. 5. Importance of the C-terminal tripeptide (Lys-Pro-Val).

Journal of medicinal chemistry, 1984 Sep. review.

[20]

Drugs@FDA/openFDA query for KPV

U.S. Food and Drug Administration / openFDA. database query.

[21]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[22]

July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee

U.S. Food and Drug Administration, 2026-04-16. regulatory.

[23]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[24]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.